首页|达格列净治疗2型糖尿病合并慢性心力衰竭患者的效果

达格列净治疗2型糖尿病合并慢性心力衰竭患者的效果

扫码查看
原文链接
  • 国家科技期刊平台
  • NETL
  • NSTL
  • 万方数据
  • 维普
目的:探讨2型糖尿病(T2DM)合并慢性心力衰竭(CHF)患者通过达格列净治疗的效果。方法:选取2021年1 月—2022 年 12 月于甘肃省康复中心医院就诊的 180 例T2DM合并CHF患者作为研究对象，按信封随机法将患者分为试验组和对照组，各 90 例。对照组施行二甲双胍治疗，试验组施行达格列净治疗，对比较两组临床疗效、心功能、血糖水平、血清可溶性基质裂解素 2(ST2)、生长分化因子-15(GDF-15)、血管性血友病因子(vWF)水平。结果:试验组总有效率为 93。33%，高于对照组的 83。33%，差异有统计学意义(P<0。05)。治疗 12 周后，两组左室舒张末期压力、血糖降低，左室收缩末期压力、左室缩短分数提高，且试验组左室舒张末期压力、餐后 2 h血糖和空腹血糖低于对照组，左室收缩末期压力、左室缩短分数高于对照组，差异有统计学意义(P<0。05)。治疗 12 周后，两组血清ST2、vWF与GDF-15 水平降低，且试验组低于对照组，差异有统计学意义(P<0。05)。结论:在T2DM合并CHF的治疗中，达格列净效果显著，有助于降低血清ST2、GDF-15 与vWF水平，改善心功能，并促进血糖降低。
Effect of Dapagliflozin in the Treatment of Patients with Type 2 Diabetes Mellitus Complicated with Chronic Heart Failure
Objective:To investigate the effect of Dapagliflozin in patients with type 2 diabetes mellitus(T2DM)complicated with chronic heart failure(CHF).Method:A total of 180 patients with T2DM complicated and CHF who admitted to Gansu Rehabilitation Center Hospital from January 2021 to December 2022 were selected as the study objects,and they were randomly divided into the experimental group and the control group according to the envelope method,90 cases in each group.The control group was treated with Metformin,while the experimental group was treated with Dapagliflozin.The clinical efficacy,cardiac function,blood glucose levels,serum soluble matrix lysin 2(ST2),growth differentiation factor-15(GDF-15),von Willebrand factor(vWF)levels were compared between two groups.Result:The total effective rate in the experimental group was 93.33%,which was higher than 83.33%in the control group,the difference was statistically significant(P<0.05);after 12 weeks of treatment,the left ventricular end-diastolic pressure and blood glucose of two groups decreased,the left ventricular end-systolic pressure and left ventricular shortening fraction increased,and the left ventricular end-diastolic pressure,2 h postprandial blood glucose and fasting blood glucose of the experimental group were lower than those of the control group,and the left ventricular end-systolic pressure and left ventricular shortening fraction were higher than those of the control group,the differences were statistically significant(P<0.05);after 12 weeks of treatment,the serum ST2,vWF and GDF-15 levels in two groups decreased,and those in the experimental group were lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion:In the treatment of T2DM complicated with CHF,Dapagliflozin has a significant effect,which helps to reduce serum ST2,GDF-15 and vWF levels,improve cardiac function,and promote blood glucose levels.

Type 2 diabetes mellitusGrowth differentiation factor-15DapagliflozinVascular hemophilia factorChronic cardiac failure

徐永权、刘海、董雯丽

展开 >

甘肃省康复中心医院 甘肃 兰州 730000

2型糖尿病 生长分化因子-15 达格列净 血管性血友病因子 慢性心力衰竭

2024

10.14033/j.cnki.cfmr.2024.11.010

中外医学研究
中国医院管理杂志社

中外医学研究

影响因子：1.149
ISSN：1674-6805
年,卷(期)：2024.22(11)
  • 20